GlassScriptPhysician profile
Karen Costenbader
NPI 1447216825
$60,611.98
in general payments reported to CMS, 2019-2025
11 companies · $15K in 2025
The $15K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,688 · 2021: $6,261 · 2022: $13K · 2023: $17K · 2024: $6,878 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Food and Beverage: $323 · Travel and Lodging: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,235.00 |
| Food and Beverage | $322.99 |
| Travel and Lodging | $147.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24,195.00 | 2022-2025 | Benlysta |
| Biogen, INC. | $12,070.00 | 2024-2025 | |
| Amgen INC. | $8,216.00 | 2021-2023 | |
| Ucb Sa | $4,295.00 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,819.13 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $2,712.58 | 2021-2023 | Saphnelo |
| Eli Lilly and Company | $2,352.49 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $1,688.00 | 2019 | |
| Abbvie INC. | $650.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $613.78 | 2023-2025 | Ofev |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Costenbader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.